Novartis AG (NYSE:NVS) : Money flow in the Novartis AG (NYSE:NVS) stock was negative (3.57 million) on Wednesday, which shows that the investors used the strength in the stock price to reduce their holdings. The total traded value on upticks was $25.6 million, compared to $29.17 million on downticks. The total uptick to downtick ratio was 0.88, indicating the underlying weakness in the stock. Even in block trades, money flow was negative ($2.85 million), indicating selling on the strength. Downtick transaction value in block trades amounted to $2.85 million, indicating persistent selling. Novartis AG (NYSE:NVS) traded $1.72 higher at $81.31 gaining 2.16% over the previous days close.
Currently the company Insiders own 0.01% of Novartis AG shares according to the proxy statements. Institutional Investors own 9.95% of Novartis AG shares.
The company shares have dropped -19.21% from its 1 Year high price. On Jul 20, 2015, the shares registered one year high at $106.84 and the one year low was seen on Apr 1, 2016. The 50-Day Moving Average price is $78.19 and the 200 Day Moving Average price is recorded at $77.35. Novartis AG (NYSE:NVS): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $81.20 and $80.91 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $81.59. The buying momentum continued till the end and the stock did not give up its gains. It closed at $81.18, notching a gain of 2.00% for the day. The total traded volume was 2,548,407 . The stock had closed at $79.59 on the previous day.
Novartis AG is a holding company that, through its subsidiaries, is engaged in development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals around the world. Its portfolio includes medicines, eye care, generic pharmaceuticals, preventive vaccines and over-the-counter (OTC) products. The Companys segments include Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals, and Consumer Health, which includes the OTC Division. Pharmaceuticals products include Afinitor/Votubia, Exjade, Galvus, Exforge and Voltaren, among others. Its Sandoz products include Valsartan (Diovan), Cyclophosphamide injection and AirFluSal Forspiro, among others. Its OTC offers readily available consumer medicine. The Company operates Admune Therapeutics as a wholly owned subsidiary.